Press releases | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

21 Jan 2022

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study

Read More
19 Jan 2022

UCB to acquire Zogenix

Read More
18 Jan 2022

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Read More
8 Jan 2022

Disposals of own shares

Read More
3 Jan 2022

Disposals of own shares

Read More
21 Dec 2021

Disposals of own shares

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe